BBIO
BridgeBio Pharma Inc
65.60$
-1.1%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 14.6% | 34.3% | 0.3% | 27.6% | 21.9% | 35.4% | 2.3% | 3.3% | 5.4% | 10.0% | 5.4% | 6.8% | 6.9% | |
| 85.4% | 65.7% | 99.7% | 72.4% | 78.1% | 64.6% | 97.7% | 96.7% | 94.6% | 90.0% | 94.6% | 93.2% | 93.1% | |
| 3,058.8% | 7,462.8% | 66.8% | 5,290.4% | 4,408.6% | 2,216.1% | 95.5% | 100.6% | 93.5% | 92.1% | 65.1% | 67.2% | 76.7% | |
| 874.5% | 2,726.8% | 31.2% | 2,745.5% | 2,519.0% | 1,611.4% | 91.2% | 116.8% | 114.0% | 102.5% | 84.3% | 83.7% | 93.4% | |
| 3,940.0% | 10,232.8% | 99.6% | 8,169.2% | 7,096.8% | 3,907.3% | 187.2% | 218.1% | 214.9% | 210.1% | 149.1% | 141.4% | 171.7% | |
| -3,854.6% | -10,167.1% | 0.2% | -8,096.8% | -7,018.7% | -3,842.7% | -89.5% | -121.4% | -120.3% | -120.1% | -54.5% | -48.1% | -78.6% | |
| 496.4% | 1,161.5% | 11.1% | 1,058.0% | 844.1% | 507.0% | 36.1% | 34.0% | 9.7% | 7.8% | 27.2% | 6.0% | 13.0% | |
| -4,387.4% | -9,760.9% | -17.1% | -3,484.5% | -6,012.2% | -4,526.3% | -145.4% | -164.3% | -154.5% | -127.9% | -85.6% | -70.1% | -102.1% | |
| -40.1% | 1,052.0% | -0.4% | -96.3% | – | 19.6% | 1.9% | 1.9% | -1.3% | – | – | -2.8% | – | |
| -4,326.5% | -9,636.0% | -16.7% | -3,388.2% | -5,931.2% | -4,506.1% | -143.5% | -164.5% | -151.4% | -127.9% | -84.3% | -68.4% | -100.6% | |
| -3,851.0% | -8,508.6% | -5.3% | -2,353.9% | -5,111.8% | -3,996.1% | -108.2% | -129.1% | -143.6% | -116.9% | -57.9% | -61.4% | -87.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.